Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases.

Autor:	Baiges A; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Cerda E; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Amicone C; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Téllez L; Servicio Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, CIBERehd, Madrid, Spain., Alvarado-Tapias E; Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, CIBERehd, Barcelona, Spain., Puente A; Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain., Fortea JI; Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain., Llop E; Gastroenterology and Hepatology Department, IDIPHISA, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain., Rocha F; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Orts L; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Ros-Fargas O; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Vizcarra P; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Zekrini K; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Lounes OA; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Touati G; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Jiménez-Esquivel N; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Serrano MJ; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Falgà A; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Magaz M; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Olivas P; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Betancourt F; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Perez-Campuzano V; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Turon F; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Payancé A; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Goria O; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Rautou PE; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France., Hernández-Gea V; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases., Villanueva C; Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, CIBERehd, Barcelona, Spain., Albillos A; Servicio Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, CIBERehd, Madrid, Spain., Plessier A; Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: aurelie.plessier@aphp.fr., García-Pagán JC; Hepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases. Electronic address: jcgarcia@clinic.cat.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2022 Jul; Vol. 20 (7), pp. 1525-1533.e5. Date of Electronic Publication: 2021 Dec 27.
DOI:	10.1016/j.cgh.2021.12.032
Abstrakt:	Background & Aims: Vascular liver diseases (VLDs) are represented mainly by portosinusoidal vascular disease (PSVD), noncirrhotic splanchnic vein thrombosis (SVT), and Budd Chiari syndrome (BCS). It is unknown whether patients with VLDs constitute a high-risk population for complications and greater coronavirus disease 2019 (COVID-19)-related mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLDs, as well as to assess its impact on hepatic decompensation and survival. Methods: This is an observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLDs between March 2020 and March 2021, compared with the general population (GP). Patients from Spain (5 centers; n = 493) and France (1 center; n = 475) were included. Results: Nine hundred sixty-eight patients were included: 274 with PSVD, 539 with SVT, and 155 with BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 with PSVD, 77 with SVT, and 8 with BCS. The prevalence of SARS-CoV-2 infection in patients with PSVD (19%) and SVT (14%) was significantly higher than in the GP (6.5%; P < .05), whereas it was very similar in patients with BCS (5%). In terms of infection severity, patients with VLDs also presented a higher need of hospital admission (14% vs 7.3%; P < .01), intensive care unit admission (2% vs 0.7%; P < .01), and mortality (4% vs 1.5%; P < .05) than the GP. Previous history of ascites (50% vs 8%; P < .05) and post-COVID-19 hepatic decompensation (50% vs 4%; P < .05) were associated with COVID-19 mortality. Conclusions: Patients with PSVD and SVT could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease. (Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu